TY  - JOUR
AU  - Addeo, Alfredo
AU  - Banna, Giuseppe Luigi
PY  - 2018
TI  - PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
JF  - Translational Lung Cancer Research; Vol 7, Supplement 3 (September 26, 2018): Translational Lung Cancer Research1
Y2  - 2018
KW  - 
N2  - Immune checkpoint inhibitors (ICPIs) targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) axis have dramatically expanded the therapeutic armamentarium for non-small cell lung cancer (NSCLC) and are now standard treatments for patients with advanced disease (1).
UR  - https://tlcr.amegroups.org/article/view/23046